Evaluation of Etanercept Treatment in Newborn Rat Model with Hyperoxic Lung Injury. 2016

Guven Kaya, and Mehmet Saldir, and Adem Polat, and M Kursat Fidanci, and Aysegul Erdem, and Galip Erdem, and Yasemin Gulcan Kurt, and Merih Cetinkaya, and Ferhat Cekmez, and Onder Onguru, and Turan Tunc
a Department of Pediatrics , Gulhane Military School of Medicine , Ankara , Turkey.

BACKGROUND Many factors contribute to the development of BPD basically by increasing inflammation in preterm lungs. However, premature neonates have insufficient anti-inflammatory capacity. We aimed to evaluate the effect of etanercept, an anti-TNF agent, on BPD development in newborn rat model with hyperoxia-induced lung injury. METHODS Thirty-two newborn rats were divided into 3 groups as control group (Group 1, n = 11), hyperoxia + placebo group (Group 2, n = 10), and hyperoxia + etanercept group (Group 3, n = 11). Histopathological and biochemical analysis were performed in order to assess inflammation and oxidative stress. Superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) activities, and malondialdehyde (MDA) levels were studied, histopathological scoring and radial alveolar count were applied in lung tissue. Lamellar body membrane protein, vascular endothelial growth factor (VEGF), nuclear factor-kappaB (NF-κB) gene expressions were studied in immunohistochemical evaluation of tissue samples. All three groups were compared with each other in terms of all parameters. RESULTS SOD and GSH-Px activities were significantly higher, whereas MDA levels were lower in group 3, compared to group 2 (p < 0.001). Histopathological scores were lower, lamellar body membrane protein expression and radial alveolar count were higher in group 3 (p < 0.05). NF-κB expression was higher in group 2, but lower in group 3 in comparison with group 1. Expression of VEGF was decreased in group 2 but came close to group 1 with etanercept treatment in group 3. CONCLUSIONS We found etanercept treatment to be protective in newborn rats with hyperoxia-induced lung damage.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000068800 Etanercept A recombinant version of soluble human TNF receptor fused to an IgG FC fragment that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS. Enbrel,Erelzi,Etanercept-szzs,Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,TNF Receptor Type II-IgG Fusion Protein,TNFR-Fc Fusion Protein,TNR 001,TNR-001,TNT Receptor Fusion Protein,TNTR-Fc,Fusion Protein, TNFR-Fc,Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein,TNF Receptor Type II IgG Fusion Protein,TNFR Fc Fusion Protein,TNR001
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000831 Animals, Newborn Refers to animals in the period of time just after birth. Animals, Neonatal,Animal, Neonatal,Animal, Newborn,Neonatal Animal,Neonatal Animals,Newborn Animal,Newborn Animals
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D055371 Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological). Lung Injury, Acute,Acute Lung Injuries,Lung Injuries, Acute

Related Publications

Guven Kaya, and Mehmet Saldir, and Adem Polat, and M Kursat Fidanci, and Aysegul Erdem, and Galip Erdem, and Yasemin Gulcan Kurt, and Merih Cetinkaya, and Ferhat Cekmez, and Onder Onguru, and Turan Tunc
January 2016, Journal of investigative surgery : the official journal of the Academy of Surgical Research,
Guven Kaya, and Mehmet Saldir, and Adem Polat, and M Kursat Fidanci, and Aysegul Erdem, and Galip Erdem, and Yasemin Gulcan Kurt, and Merih Cetinkaya, and Ferhat Cekmez, and Onder Onguru, and Turan Tunc
August 2013, Free radical biology & medicine,
Guven Kaya, and Mehmet Saldir, and Adem Polat, and M Kursat Fidanci, and Aysegul Erdem, and Galip Erdem, and Yasemin Gulcan Kurt, and Merih Cetinkaya, and Ferhat Cekmez, and Onder Onguru, and Turan Tunc
September 2008, Zhonghua er ke za zhi = Chinese journal of pediatrics,
Guven Kaya, and Mehmet Saldir, and Adem Polat, and M Kursat Fidanci, and Aysegul Erdem, and Galip Erdem, and Yasemin Gulcan Kurt, and Merih Cetinkaya, and Ferhat Cekmez, and Onder Onguru, and Turan Tunc
February 1992, Prostaglandins, leukotrienes, and essential fatty acids,
Guven Kaya, and Mehmet Saldir, and Adem Polat, and M Kursat Fidanci, and Aysegul Erdem, and Galip Erdem, and Yasemin Gulcan Kurt, and Merih Cetinkaya, and Ferhat Cekmez, and Onder Onguru, and Turan Tunc
July 2013, Pediatric research,
Guven Kaya, and Mehmet Saldir, and Adem Polat, and M Kursat Fidanci, and Aysegul Erdem, and Galip Erdem, and Yasemin Gulcan Kurt, and Merih Cetinkaya, and Ferhat Cekmez, and Onder Onguru, and Turan Tunc
July 2020, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians,
Guven Kaya, and Mehmet Saldir, and Adem Polat, and M Kursat Fidanci, and Aysegul Erdem, and Galip Erdem, and Yasemin Gulcan Kurt, and Merih Cetinkaya, and Ferhat Cekmez, and Onder Onguru, and Turan Tunc
January 2021, Journal of neonatal-perinatal medicine,
Guven Kaya, and Mehmet Saldir, and Adem Polat, and M Kursat Fidanci, and Aysegul Erdem, and Galip Erdem, and Yasemin Gulcan Kurt, and Merih Cetinkaya, and Ferhat Cekmez, and Onder Onguru, and Turan Tunc
January 1991, Free radical biology & medicine,
Guven Kaya, and Mehmet Saldir, and Adem Polat, and M Kursat Fidanci, and Aysegul Erdem, and Galip Erdem, and Yasemin Gulcan Kurt, and Merih Cetinkaya, and Ferhat Cekmez, and Onder Onguru, and Turan Tunc
January 2008, Physiological research,
Guven Kaya, and Mehmet Saldir, and Adem Polat, and M Kursat Fidanci, and Aysegul Erdem, and Galip Erdem, and Yasemin Gulcan Kurt, and Merih Cetinkaya, and Ferhat Cekmez, and Onder Onguru, and Turan Tunc
April 1997, Pediatric research,
Copied contents to your clipboard!